Dynamics of an unguided missiles launcher

The paper discussed the modelling, examination of the dynamic properties and stability of the WW-4 launcher of unguided short-range missiles NLPR-70. Remotely controlled armament module ZSMU-70, in the presented configuration, is designed to combat ground targets in form of light armoured vehicles. The purpose of this paper is to present a physical model, a mathematical model and computer simulation of launcher motion during launching and the first phase of flight of the missile. The virtual model is formulated in the vertical plane and verified by experimental studies. The theoretical model corresponds to experimental studies conducted at the military testing ground with application of a high-speed camera

Dynamics of an unguided missiles launcher

The paper discussed the modelling, examination of the dynamic properties and stability of the WW-4 launcher of unguided short-range missiles NLPR-70. Remotely controlled armament module ZSMU-70, in the presented configuration, is designed to combat ground targets in form of light armoured vehicles. The purpose of this paper is to present a physical model, a mathematical model and computer simulation of launcher motion during launching and the first phase of flight of the missile. The virtual model is formulated in the vertical plane and verified by experimental studies. The theoretical model corresponds to experimental studies conducted at the military testing ground with application of a high-speed camera

Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib - Analysis of prognostic factors (EORTC-STBSG collaborative study)

Background Long-term complete remissions remain a rare exception in patients with metastatic gastrointestinal stromal tumors (GIST) treated with IM (imatinib). To date the therapeutic relevance of surgical resection of metastatic disease remains unknown except for the use in palliative intent. Patients and methods We analyzed overall survival (OS) and progression-free survival (PFS) in consecutive patients with metastatic GIST who underwent metastasectomy and received IM therapy (n = 239). Results Complete resection (R0+R1) was achieved in 177 patients. Median OS was 8.7 y for R0/R1 and 5.3 y in pts with R2 resection (p = 0.0001). In the group who were in remission at time of resection median OS was not reached in the R0/R1 surgery and 5.1 y in the R2-surgery (p = 0.0001). Median time to relapse/progression after resection of residual disease was not reached in the R0/R1 and 1.9 years in the R2 group of patients, who were resected in response. No difference in mPFS was seen in patients progressing at time of surgery. Conclusions: Our analysis implicates possible long-term survival in patients in whom surgical complete remission can be achieved. Incomplete resection, including debulking surgery does not seem to prolong survival. Despite the retrospective character and likely selection bias, this analysis may help in decision making for surgical approaches in metastatic GIST

Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience

Contains fulltext : 125703.pdf (publisher's version ) (Closed access)BACKGROUND: Preoperative imatinib therapy of locally advanced GIST may facilitate resection and decrease morbidity of the procedure. METHODS: We have pooled databases from 10 EORTC STBSG sarcoma centers and analyzed disease-free survival (DFS) and disease-specific survival (DSS) in 161 patients with locally advanced, nonmetastatic GISTs who received neoadjuvant imatinib. OS was calculated from start of imatinib therapy for locally advanced disease until death or last follow-up (FU) after resection of the GIST. DFS was calculated from date of resection to date of disease recurrence or last FU. Median FU time was 46 months. RESULTS: The primary tumor was located in the stomach (55 %), followed by rectum (20 %), duodenum (10 %), ileum/jejunum/other (11 %), and esophagus (3 %). The tumor resection after preoperative imatinib (median time on therapy, 40 weeks) was R0 in 83 %. Only two patients have demonstrated disease progression during neoadjuvant therapy. Five-year DSS/DFS rates were 95/65 %, respectively, median OS was 104 months, and median DFS was not reached. There were 56 % of patients who continued imatinib after resection. Thirty-seven GIST recurrences were diagnosed (only 5 local relapses). The most common mutations affected exon 11 KIT (65 %). Poorer DFS was related to primary tumor location in small bowel and lack of postoperative therapy with imatinib. CONCLUSIONS: Our analysis comprising the largest group of GIST patients treated with neoadjuvant imatinib in routine practice indicates excellent long-term results of combined therapy in locally advanced GISTs